April 8 (Reuters) - SeaStar Medical Holding Corp ICU.O:
FDA GRANTS SEASTAR MEDICAL TWO NEW BREAKTHROUGH DEVICE DESIGNATIONS FOR SCD THERAPY TO TREAT SYSTEMIC INFLAMMATORY RESPONSE IN ADULT AND PEDIATRIC PATIENTS UNDERGOING CARDIAC SURGERY
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.